IPI-504 News
Most Popular IPI-504 Story
AZ returns rights to two oncology programs
AstraZeneca has handed back the rights to two oncology programs it picked up in the 2007 acquisition of MedImmune. Infinity Pharmaceuticals gets the full rights to IPI-504 and IPI-493, both of which Read more...
Latest Headlines
- April 15, 2009
- December 11, 2008
- July 16, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
